Pin1 plays a key role in the response to treatment and clinical outcome in triple negative breast cancer.

ABSTRACT:

Background

Triple negative breast cancer (TNBC) is the subset of breast cancer associated with the poorest outcome, and currently lacks targeted treatments. Standard of care (SoC) chemotherapy often consists of DNA damaging chemotherapies ± taxanes, with a range of responses observed. However, we currently lack biomarkers to predict this response and lack alternate treatment options.

Methods

Pin1 expression was modulated in vitro and proliferation and treatment response was studied. Pin1 expression was analysed in patient samples and correlated with clinical outcome.

Results

In this study, we have shown that the prolyl isomerase, Pin1, which is highly expressed in TNBC, plays a key role in pathogenesis of the disease. Knockdown of Pin1 in TNBC resulted in cell

SUBMITTER: Knowlson C 

PROVIDER: S-EPMC7065279 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature